Lawrence Billing

Lawrence Billing is a Senior Scientist at Nuntius Therapeutics since March 2022, focusing on the development of next-generation cell-specific gene therapies, including asset development and experimental design. Prior to this role, Lawrence worked as a Scientist at Mogrify (October 2019 - March 2022), where involvement included cell-based immunotherapy development utilizing methods such as stem cell differentiation and genome editing. A position as a Research Associate at Kallyope (February 2019 - August 2019) involved establishing a translational in vitro drug discovery platform using human intestinal organoids. Earlier, a Wellcome Trust funded Vacation Project at the University of Cambridge provided research experience. Lawrence holds a PhD in Metabolic Disease, an MRes in Medical Science, and an MA in Natural Sciences, all from the University of Cambridge, along with A-levels and GCSEs from Farnborough Sixth Form College and Court Moor School, respectively.